IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A pharmaceutical composition for improving cerebral function which comprises comprising the following ingredients (A) and (B):

Ingredient (A): An alkyl ether derivative represented by the following formula:

$$R^{1}$$
— CH - $(CH_{2})_{m}$ - O — $(CH_{2})_{\overline{n}}$ - N
 R^{4}

wherein R¹ represents a substituted or unsubstituted heterocyclic group; R² represents a hydrogen atom or a hydroxyl group; R³ and R⁴, which may be the same or different, each represents a substituted or unsubstituted alkyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a substituted or unsubstituted cyclic amino group; m represents an integer of 1 to 5; and n represents an integer of 1 to 6; or a salt thereof,

Ingredient (B): A compound having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

Claim 2 (Currently Amended): A pharmaceutical composition for improving cerebral function according to Claim 1, wherein in the formula of ingredient (A), R¹, R², R³, R⁴, m and n meet any one of the following conditions (1) to (3):

(1) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R² is a hydroxyl group; R³ is an alkyl group; R⁴ is an alkyl group which may be substituted with an alkoxy-substituted phenyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2; or a salt thereof,

- (2) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group which may be substituted with a hydroxyl group, an alkoxy group, a carboxyl group, an aminocarbonyl group, a hydroxyl group, an alkylthio group, a phenyl group and a pyridyl group; R² is a hydrogen atom; R³ is an alkyl group which may be substituted with a group selected from a phenyl group which may be substituted with a halogen atom, an alkoxy group or a nitro group, an optionally protected hydroxyl group, an alkylamino group and an alkynyl group; R⁴ is an alkyl group which may be substituted with a phenyl group; m is 1; and n is 2 to 3; or a salt thereof,
- (3) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R² is a hydrogen atom; R³ or R⁴ is an alkyl group which may be substituted with a group selected from a hydroxyl group, an optionally protected amino group and an alkylamino group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2 to 3; or a salt thereof.

Claim 3 (Currently Amended): A pharmaceutical composition for improving cerebral function according to Claim 1 or 2, wherein ingredient (B) is at least one compound selected from Tacrine, Donepezil, Rivastigmine, Galanthamine, Huperdine, Ipidacrine, Zanapezil, Phenserine, Quilostigmine, Ganstigmine, Ensaculin and T-82.

Claim 4 (Currently Amended): A method of preparing a medicament comprising combining the following using the following ingredients (A) and (B) in combination in order to improve cerebral function,

Ingredient (A): An alkyl ether derivative represented by the following formula:

$$R^{1}$$
— CH - $(CH_{2})_{m}$ - O - $(CH_{2})_{\overline{n}}$ - N
 R^{4}

wherein R¹ represents a substituted or unsubstituted heterocyclic group; R² represents a hydrogen atom or a hydroxyl group; R³ and R⁴, which may be the same or different, each represents a substituted or unsubstituted alkyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a substituted or unsubstituted cyclic amino group; m represents an integer of 1 to 5; and n represents an integer of 1 to 6; or a salt thereof,

Ingredient (B): A compound having an acetylcholine esterase inhibitory activity or a salt thereof, which is different from ingredient (A).

Claim 5 (Original): A method according to Claim 4, wherein in the formula of ingredient (A), R¹, R², R³, R⁴, m and n meet any one of the following conditions (1) to (3):

- (1) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R² is a hydroxyl group; R³ is an alkyl group; R⁴ is an alkyl group which may be substituted with an alkoxy-substituted phenyl group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2; or a salt thereof,
- (2) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group which may be substituted with a hydroxyl group, an alkoxy group, a carboxyl group, an aminocarbonyl group, a hydroxyl group, an alkylthio group, a phenyl group and a pyridyl group; R² is a hydrogen atom; R³ is an alkyl group which may be substituted with a group

selected from a phenyl group which may be substituted with a halogen atom, an alkoxy group or a nitro group, an optionally protected hydroxyl group, an alkylamino group and an alkynyl group; R⁴ is an alkyl group which may be substituted with a phenyl group; m is 1; and n is 2 to 3; or a salt thereof,

(3) An alkyl ether derivative wherein R¹ is a benzothienyl or benzofuranyl group which may be substituted with a group selected from a halogen atom, an alkyl group and a phenyl group; R² is a hydrogen atom; R³ or R⁴ is an alkyl group which may be substituted with a group selected from a hydroxyl group, an optionally protected amino group and an alkylamino group, or R³ and R⁴, taken conjointly with the nitrogen atom to which R³ and R⁴ are linked, form an azetidine ring, a pyrrolidine ring, a piperidine ring, a piperazine ring or a morpholine ring; m is 1; and n is 2 to 3; or a salt thereof.

Claim 6 (Currently Amended): A method according to Claim 4 or 5, wherein ingredient (B) is at least one compound selected from Tacrine, Donepezil, Rivastigmine, Galanthamine, Huperzine, Ipidacrine, Zanapezil, Phenserine, Quilostigmine, Ganstigmine, Ensaculin and T-82.

Claim 7 (New): A pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is administered to a patient to improve cerebral function.

Claim 8 (New): A method as claimed in claim 4 further comprising administering the medicament to a patient in order to improve cerebral function.